JPH06504778A - 肺血管収縮及び喘息の治療法 - Google Patents
肺血管収縮及び喘息の治療法Info
- Publication number
- JPH06504778A JPH06504778A JP4502844A JP50284492A JPH06504778A JP H06504778 A JPH06504778 A JP H06504778A JP 4502844 A JP4502844 A JP 4502844A JP 50284492 A JP50284492 A JP 50284492A JP H06504778 A JPH06504778 A JP H06504778A
- Authority
- JP
- Japan
- Prior art keywords
- gas
- conduit
- compound
- nitric oxide
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008695 pulmonary vasoconstriction Effects 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims description 41
- 208000006673 asthma Diseases 0.000 title description 30
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 361
- 238000000034 method Methods 0.000 claims abstract description 32
- 206010006482 Bronchospasm Diseases 0.000 claims abstract description 22
- 230000007885 bronchoconstriction Effects 0.000 claims abstract description 21
- 241000124008 Mammalia Species 0.000 claims abstract description 17
- 239000002840 nitric oxide donor Substances 0.000 claims abstract description 14
- 239000007789 gas Substances 0.000 claims description 109
- 150000001875 compounds Chemical class 0.000 claims description 64
- 210000004072 lung Anatomy 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 26
- 230000001684 chronic effect Effects 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 239000003380 propellant Substances 0.000 claims description 15
- 229940124630 bronchodilator Drugs 0.000 claims description 14
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 13
- 229960002460 nitroprusside Drugs 0.000 claims description 13
- 210000002345 respiratory system Anatomy 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 claims description 9
- 230000004199 lung function Effects 0.000 claims description 8
- 230000007246 mechanism Effects 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 7
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical class [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 7
- 150000001540 azides Chemical class 0.000 claims description 6
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 6
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 claims description 5
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims description 3
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 3
- 229960000265 cromoglicic acid Drugs 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XHRCFGDFESIFRG-UHFFFAOYSA-N 2-chloro-n-ethyl-n-[(2-methylphenyl)methyl]ethanamine Chemical group ClCCN(CC)CC1=CC=CC=C1C XHRCFGDFESIFRG-UHFFFAOYSA-N 0.000 claims 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims 1
- 229960004448 pentamidine Drugs 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 abstract description 11
- 230000002685 pulmonary effect Effects 0.000 description 32
- 229910052760 oxygen Inorganic materials 0.000 description 31
- 208000002815 pulmonary hypertension Diseases 0.000 description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 29
- 239000001301 oxygen Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- 230000001154 acute effect Effects 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 238000005259 measurement Methods 0.000 description 20
- 206010021143 Hypoxia Diseases 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 230000036593 pulmonary vascular resistance Effects 0.000 description 17
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 16
- 229960002329 methacholine Drugs 0.000 description 16
- 230000009885 systemic effect Effects 0.000 description 16
- 241000283903 Ovis aries Species 0.000 description 15
- 230000004872 arterial blood pressure Effects 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 15
- 241000700198 Cavia Species 0.000 description 14
- 230000029058 respiratory gaseous exchange Effects 0.000 description 14
- 230000007423 decrease Effects 0.000 description 13
- 230000007954 hypoxia Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000025033 vasoconstriction Effects 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 11
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 10
- 206010047139 Vasoconstriction Diseases 0.000 description 10
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 230000024883 vasodilation Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000002664 inhalation therapy Methods 0.000 description 9
- 241000700199 Cavia porcellus Species 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 229940048914 protamine Drugs 0.000 description 8
- 210000001147 pulmonary artery Anatomy 0.000 description 8
- 230000032258 transport Effects 0.000 description 8
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- -1 nitrosyl compound Chemical class 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229960000195 terbutaline Drugs 0.000 description 7
- 230000000304 vasodilatating effect Effects 0.000 description 7
- 238000009423 ventilation Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 206010038687 Respiratory distress Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000006199 nebulizer Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229940124549 vasodilator Drugs 0.000 description 6
- 239000003071 vasodilator agent Substances 0.000 description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 241000283898 Ovis Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000168 bronchodilator agent Substances 0.000 description 5
- 239000000480 calcium channel blocker Substances 0.000 description 5
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000002464 muscle smooth vascular Anatomy 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 210000000621 bronchi Anatomy 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 208000000122 hyperventilation Diseases 0.000 description 4
- 230000000870 hyperventilation Effects 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000036581 peripheral resistance Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000007883 bronchodilation Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 208000028831 congenital heart disease Diseases 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 208000005333 pulmonary edema Diseases 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- 230000008704 pulmonary vasodilation Effects 0.000 description 3
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 208000008445 altitude sickness Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005399 mechanical ventilation Methods 0.000 description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000003278 patent ductus arteriosus Diseases 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 230000004088 pulmonary circulation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004071 soot Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000032589 Diaphragmatic Congenital Hernias Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000003241 Fat Embolism Diseases 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 206010019372 Heinz bodies Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 208000003898 Mediastinal Emphysema Diseases 0.000 description 1
- 208000034388 Mountain sickness acute Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910002089 NOx Inorganic materials 0.000 description 1
- ZWHAWGKTHSGQTA-OURVEVOKSA-N N[C@@H](CS[S+](C[C@@H](C([O-])=O)N)N=O)C(O)=O Chemical compound N[C@@H](CS[S+](C[C@@H](C([O-])=O)N)N=O)C(O)=O ZWHAWGKTHSGQTA-OURVEVOKSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001184 Oligohydramnios Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 208000008883 Patent Foramen Ovale Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010050184 Pneumomediastinum Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010048731 Pneumopericardium Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 101710108416 Robin Proteins 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- 102100035115 Testin Human genes 0.000 description 1
- 101710070533 Testin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- 241000710779 Trina Species 0.000 description 1
- CYBACPSHBXABHX-SUYDQAKGSA-N [(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O CYBACPSHBXABHX-SUYDQAKGSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000032912 absorption of UV light Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000018315 acute mountain sickness Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000008371 airway function Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 231100001012 cardiac lesion Toxicity 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000005890 congenital diaphragmatic hernia Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000009560 cranial ultrasound Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000004491 foramen ovale Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 210000001907 heinz body Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000008706 hypoxic vasoconstriction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 231100000037 inhalation toxicity test Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 208000024710 intermittent asthma Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QEHKBHWEUPXBCW-UHFFFAOYSA-N nitrogen trichloride Chemical compound ClN(Cl)Cl QEHKBHWEUPXBCW-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000012191 relaxation of muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000020994 smoked meat Nutrition 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Glass Compositions (AREA)
- Saccharide Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Exhaust Gas Treatment By Means Of Catalyst (AREA)
Abstract
Description
Claims (38)
- 1.哺乳類における肺機能の改善のための、吸入可能な薬物の製造における酸化 窒素供給源の使用。
- 2.哺乳類における肺機能の改善のため有用な装置の製造における酸化窒素供給 源の使用。
- 3.哺乳類における慢性肺血管収縮解消の診断に有用な診断薬の製造における酸 化窒素供給源の使用。
- 4.前記哺乳類が肺血管収縮を患っていることを特徴とする請求項1または2に 記載の使用。
- 5.前記哺乳類が気管支収縮を患っていることを特徴とする請求項1または2に 記載の使用。
- 6.前記吸入可能な薬物が酸化窒素ガスを含有することを特徴とする請求項1に 記載の使用。
- 7.前記装置が酸化窒素ガスを含有することを特徴とする請求項2に記載の使用 。
- 8.前記診断薬が酸化窒素ガスを含有するガス混合物であることを特徴とする請 求項3に記載の使用。
- 9.酸化窒素の供給源が酸化窒素放出化合物であることを特徴とする請求項1〜 5のいずれかに記載の使用。
- 10.前記酸化窒素放出化合物が、S−ニトロソ−N−アセチルペニシラミン、 S−ニトロソシステイン、ニトロプルシド、ニトロソグアニジン、グリセリルト リナイトレート、イソアミル亜硝酸塩、無機亜硝酸塩、アジド、またはヒドロキ シルアミンであることを特徴とする請求項9に記載の使用。
- 11.前記装置が前記哺乳類の肺への酸化窒素の輸送を容易にするよう設計され ていることを特徴とする請求項7に記載の使用。
- 12.前記気管支収縮が消息に関連することを特徴とする請求項5に記載の使用 。
- 13.酸化窒素の供給源と、前記供給源を肺機能の改善に使用するための説明書 を有するキット。
- 14.前記酸化窒素供給源が圧縮ガスの容器であることを特徴とする請求項13 に記載のキット。
- 15.前記酸化窒素供給源が酸化窒素放出化合物であることを特徴とする請求項 13に記載のキット。
- 16.前記説明書が前記酸化窒素または前記酸化窒素供給源の吸入を特定するこ とを特徴とする請求項13に記載のキット。
- 17.最低1ppmの酸化窒素を含有する圧縮ガスを含む容器と、導管を有する 外箱(前記容器が前記外箱に連結していることにより、前記ガスを前記導管中に 輸送する)と、 前記ガスを前記容器から前記導管に制御可能な様式で放出する機構を有する吸入 器装置、ここで、前記導管はヒトの呼吸系に放出ガスを輸送するよう配置されて おり、前記装置の重量は約5kg以下である。
- 18.前記装置の重量が約1kg以下であることを特徴とする請求項17に記載 の装置。
- 19.前記圧縮ガスがN2を付加的に含有することを特徴とする請求項17に記 載の装置。
- 20.前記導管が再呼吸チャンバーを有することを特徴とする請求項17に記載 の装置。
- 21.前記容器が液化推進薬を付加的に含有することを特徴とする請求項17に 記載の装置。
- 22.(a)吸入可能な薬理学的に活性のある薬物を含有するチャンバー、及び (b)前記チャンバーに連結した導管を有する外箱と、最低1ppmの酸化窒素 を含有する圧縮ガスを含む容器を有する吸入器装置、ここで、前記容器は前記導 管に制御可能な様式で放出する機構を有するため、前記薬物を前記放出ガスに懸 濁する;前記導管は患者の呼吸系に放出ガスを輸送するよう配置されている。
- 23.前記薬理学的に活性のある薬物が液状または固体状の気管支拡張化合物を 含有することを特徴とする請求項22に記載の装置。
- 24.前記化合物が抗コリン作動薬、αβ2アゴニスト、メチルキサンチン、カ ルシウムチャネル遮断薬、グルココルチコイド薬物、またはクロモリンナトリウ ムを含有することを特徴とする請求項23に記載の装置。
- 25.前記薬理学的に活性のある薬物が酸化窒素放出化合物を含有することを特 徴とする請求項22に記載の装置。
- 26.前記化合物が、S−ニトロソ−N−アセチルペニシラミン、S−ニトロソ システイン、ニトロプルシド、ニトロソグアニジン、グリセリルトリナイトレー ト、イソアミル亜硝酸塩、無機亜硝酸塩、アジド、またはヒドロキシルアミンを 含む群から選択されることを特徴とする請求項25に記載の装置。
- 27.前記薬理学的に活性のある薬物が抗菌剤を含有することを特徴とする請求 項22に記載の装置。
- 28.前記抗菌剤が抗生物質を含有することを特徴とする請求項27に記載の装 置。
- 29.前記抗菌剤がペンタミジンを含有することを特徴とする請求項27に記載 の装置。
- 30.前記薬理学的に活性のある薬物がヒアリン膜疾患の治療に適した界面活性 剤を含有することを特徴とする請求項22に記載の装置。
- 31.前記容器が前記ガスを制御可能な様式で、前記チャンバーを迂回して前記 導管に放出する機構も有することを特徴とする請求項22に記載の装置。
- 32.圧縮または液化された推進薬ガス中に懸濁された酸化窒素供与体を含有す る容器と、 (a)前記容器を搭載するポート、及び(b)前記ポートに連結した導管を有す る外箱と、 前記推進薬を前記容器から制御可能な様式で前記導管に放出し、これにより前記 懸濁化合物を前記容器から前記導管に放出する機構を有する装置、ここで、前記 導管はヒトの呼吸系に、前記放出推進薬中に懸濁された前記化合物を輸送するよ う配置されている。
- 33.前記化合物が粉末状であることを特徴とする請求項32に記載の装置。
- 34.前記化合物が生物学的に適合性のある液体担体中に溶解または懸濁されて いることを特徴とする請求項32に記載の装置。
- 35.前記化合物が、S−ニトロソ−N−アセチルペニシラミン、S−ニトロソ システイン、ニトロプルシド、ニトロソグアニジン、グリセリルトリナイトレー ト、イソアミル亜硝酸塩、無機亜硝酸塩、アジド、またはヒドロキシルアミンで あることを特徴とする請求項32に記載の装置。
- 36.圧縮または液化された推進薬を含有する容器と、(a)酸化窒素供与体化 合物を含有するチャンバー、及び(b)前記チャンバーに連結した導管を有する 外箱と、 前記容器から前記導管に制御可能な様式で前記ガスを放出し、これにより前記化 合物を前記ガスに懸濁する機構を有する装置、ここで、前記導管はヒトの呼吸系 に前記化合物を輸送するよう配置されている。
- 37.前記ガスが酸化窒素ガスを含有することを特徴とする請求項36に記載の 装置。
- 38.前記酸化窒素供与体化合物が、S−ニトロソ−N−アセチルペニシラミン 、S−ニトロソシステイン、ニトロプルシド、ニトロソグアニジン、グリセリル トリナイトレート、イソアミル亜硝酸塩、無機亜硝酸塩、アジド、またはヒドロ キシルアミンであることを特徴とする請求項36に記載の装置。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62286590A | 1990-12-05 | 1990-12-05 | |
US622,865 | 1990-12-05 | ||
US76723491A | 1991-09-27 | 1991-09-27 | |
US767,234 | 1991-09-27 | ||
PCT/US1991/009111 WO1992010228A1 (en) | 1990-12-05 | 1991-12-05 | Devices for treating pulmonary vasoconstriction and asthma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03678597A Division JP3510755B2 (ja) | 1990-12-05 | 1997-02-20 | 気管支収縮を伴う患者を治療する薬剤組成物及びその使用法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06504778A true JPH06504778A (ja) | 1994-06-02 |
JP2701978B2 JP2701978B2 (ja) | 1998-01-21 |
Family
ID=27089304
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4502844A Expired - Lifetime JP2701978B2 (ja) | 1990-12-05 | 1991-12-05 | 肺血管収縮及び喘息の治療法 |
JP03678597A Expired - Lifetime JP3510755B2 (ja) | 1990-12-05 | 1997-02-20 | 気管支収縮を伴う患者を治療する薬剤組成物及びその使用法 |
JP2002217936A Expired - Lifetime JP3718491B2 (ja) | 1990-12-05 | 2002-07-26 | 吸入用装置 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03678597A Expired - Lifetime JP3510755B2 (ja) | 1990-12-05 | 1997-02-20 | 気管支収縮を伴う患者を治療する薬剤組成物及びその使用法 |
JP2002217936A Expired - Lifetime JP3718491B2 (ja) | 1990-12-05 | 2002-07-26 | 吸入用装置 |
Country Status (17)
Country | Link |
---|---|
US (2) | US5873359A (ja) |
EP (4) | EP1875917A3 (ja) |
JP (3) | JP2701978B2 (ja) |
AT (3) | ATE158509T1 (ja) |
AU (1) | AU657726B2 (ja) |
CA (1) | CA2097823C (ja) |
DE (9) | DE69133584T4 (ja) |
DK (3) | DK0786264T3 (ja) |
EE (1) | EE03119B1 (ja) |
ES (3) | ES2288660T5 (ja) |
GR (3) | GR960300032T1 (ja) |
HK (3) | HK1020686A1 (ja) |
LU (3) | LU90886I2 (ja) |
LV (1) | LV12201B (ja) |
NL (3) | NL300081I2 (ja) |
SG (1) | SG47527A1 (ja) |
WO (1) | WO1992010228A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003186A1 (fr) * | 1996-07-18 | 1998-01-29 | Sumitomo Seika Chemicals Co., Ltd. | Gaz mixte contenant du monoxyde d'azote destine a des applications medicales, et son procede de preparation |
JP2003524630A (ja) * | 1999-09-08 | 2003-08-19 | デューク ユニバーシティ | No基化合物で心肺疾病を処置する方法 |
JP2005504001A (ja) * | 2001-02-14 | 2005-02-10 | デューク・ユニバーシティ | Gsnoの充足を起こすガス状薬剤による肺疾患の処置 |
JP2014121634A (ja) * | 2008-08-21 | 2014-07-03 | Geno Llc | 高所病を最小限に抑える及び治療するための装置及び方法 |
Families Citing this family (252)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0786264T3 (da) * | 1990-12-05 | 2008-03-10 | Gen Hospital Corp | Anordninger til behandling af pulmonal vasokonstriktion og astma |
US5570683A (en) * | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
GB9027234D0 (en) * | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
AU651882B2 (en) * | 1991-05-14 | 1994-08-04 | Visiomed Group Limited | Aerosol inhalation device |
US6029661A (en) * | 1991-08-26 | 2000-02-29 | 3M Innovative Properties Company | Powder dispenser |
DE4208880A1 (de) * | 1992-03-19 | 1993-09-23 | Boehringer Ingelheim Kg | Separator fuer pulverinhalatoren |
FR2695831B1 (fr) * | 1992-09-24 | 1994-11-10 | Air Liquide | Installation et procédé de fourniture d'un mélange gazeux aux voies respiratoires d'un utilisateur. |
US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
DE69413528T2 (de) * | 1993-04-06 | 1999-05-06 | Minnesota Mining & Mfg | Vorrichtung zum deagglomerieren für trockenpulverinhalatoren |
ATE204491T1 (de) * | 1993-04-17 | 2001-09-15 | Messer Griesheim Austria Ges M | Gerät zur kontrollierten zudosierung von no zur atemluft von patienten |
DK0724723T3 (da) * | 1993-07-06 | 2000-10-23 | Kjell Alving | System til bestemmelse af NO-Nivveauer i udåndet luft og diagnostiske metoder til forstyrrelser relateret tilunormale NO-ni |
SE501074C2 (sv) * | 1993-07-22 | 1994-11-07 | Siemens Elema Ab | Gasblandning och apparat för att tillföra gasblandningen till lungorna hos ett levande väsen |
DE4327732C1 (de) * | 1993-08-18 | 1994-09-01 | Messer Griesheim Gmbh | NO-haltiges Gasgemisch zur Behandlung pulmonaler Erkrankungen |
DE4327731C1 (de) * | 1993-08-18 | 1994-11-10 | Messer Griesheim Gmbh | NO-haltiges Gasgemisch zur Behandlung pulmonaler Erkrankungen |
GB9320978D0 (en) * | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
US5558083A (en) * | 1993-11-22 | 1996-09-24 | Ohmeda Inc. | Nitric oxide delivery system |
JP3911290B2 (ja) * | 1994-05-13 | 2007-05-09 | アラダイム コーポレーション | エアゾールを含む麻酔用処方 |
DE4419860A1 (de) * | 1994-06-07 | 1995-12-14 | Hoechst Ag | Verfahren und Filter zur Herstellung von NO¶2¶-freiem Stickstoffmonoxid mit schwefelhaltigen Polymeren |
US5615669A (en) * | 1994-07-22 | 1997-04-01 | Siemens Elema Ab | Gas mixture and device for delivering the gas mixture to the lungs of a respiratory subject |
US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
US5665077A (en) * | 1995-04-24 | 1997-09-09 | Nitrosci Pharmaceuticals Llc | Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis |
SE506208C2 (sv) | 1995-07-05 | 1997-11-24 | Aerocrine Systems Kb | Anordning för uppsamling av gas från de övre luftvägarna och leverans av denna gas till inandningsluften i en respirator |
RU2072241C1 (ru) * | 1995-09-20 | 1997-01-27 | Панина Елена Владимировна | Способ формирования дыхательной газовой смеси и аппарат для его осуществления |
EP0768095B1 (en) * | 1995-10-13 | 2001-12-19 | Siemens-Elema AB | Tracheal tube and device for ventilator systems |
AU701760B2 (en) * | 1995-10-20 | 1999-02-04 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Compound on a base of nitrogen monoxide used as a medication |
WO1997018000A1 (en) * | 1995-11-13 | 1997-05-22 | Brigham And Women's Hospital | S-nitroso-hemoglobin and therapeutic uses thereof |
US5699790A (en) * | 1996-03-21 | 1997-12-23 | Ohmeda Inc. | System for predicting NO2 concentrations |
DE69736230T2 (de) * | 1996-04-05 | 2007-05-31 | The General Hospital Corp., Boston | Behandlung einer hämoglobinstörung |
US5765548A (en) * | 1996-05-07 | 1998-06-16 | Perry; Bryan J. | Use of nitric oxide in the treatment of exercised induced pulmonary hemorrhaging in equine |
US5811437A (en) * | 1996-05-21 | 1998-09-22 | Eli Lilly And Company | Methods of increasing nitric oxide synthesis |
CA2206477A1 (en) | 1996-07-10 | 1998-01-10 | Ohmeda Inc. | System for correcting no2 monitor |
US5732694A (en) * | 1996-12-13 | 1998-03-31 | Ohmeda Inc. | System for correcting NO2 monitor |
US6720309B1 (en) * | 1996-07-17 | 2004-04-13 | Leuven Research And Development, V.Z.W. | Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene |
CA2260771A1 (en) * | 1996-07-17 | 1998-01-22 | The General Hospital Corporation | Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene |
SE9602959L (sv) * | 1996-08-12 | 1998-02-09 | Siemens Elema Ab | Förfarande vid blandning av gaser och en anordning för blandning av gaser |
AU3901497A (en) * | 1996-08-13 | 1998-03-06 | University Of Massachusetts | Nitric oxide sensor |
DE19734279A1 (de) * | 1997-08-07 | 1999-02-11 | Messer Griesheim Gmbh | Wasserstoffhaltiges Medikament |
US5732693A (en) | 1996-10-02 | 1998-03-31 | Ohmeda Inc. | Pause control of nitric oxide therapy |
WO1998031282A1 (de) | 1997-01-17 | 1998-07-23 | Messer Griesheim Austria Ges.Mbh | Gesteuertes gasversorgungssystem |
US6027713A (en) * | 1997-03-06 | 2000-02-22 | Meri Charmyne Russell | Composition and method for the treatment of exercise induced pulmonary hemorrhage |
SE9700940D0 (sv) * | 1997-03-14 | 1997-03-14 | Astra Ab | Powder inhaler IV |
CA2225013C (en) | 1997-04-04 | 2006-06-06 | Institut Du N.O. Inc. | Injection system for delivery of a gaseous substance |
AU6872698A (en) * | 1997-04-16 | 1998-11-11 | Ohmeda Inc. | Humidity compensation for fuel cell zeroing in respiratory gas measurement |
US5918596A (en) * | 1997-04-22 | 1999-07-06 | Instrumentarium Corp. | Special gas dose delivery apparatus for respiration equipment |
FR2762992B1 (fr) * | 1997-05-07 | 2000-08-25 | Air Liquide | Transporteurs de no a base de complexes polyazamacrocycles de fer et de cobalt |
US6125846A (en) * | 1997-05-16 | 2000-10-03 | Datex-Ohmeda, Inc. | Purge system for nitric oxide administration apparatus |
US6656452B1 (en) * | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
US6109260A (en) * | 1998-02-18 | 2000-08-29 | Datex-Ohmeda, Inc. | Nitric oxide administration device with timed pulse |
US6142147A (en) * | 1998-03-31 | 2000-11-07 | The General Hospital Corporation | Nasal delivery system for inhaled nitric oxide |
US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
CA2254645A1 (en) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
JP3641151B2 (ja) * | 1999-02-04 | 2005-04-20 | 帝人株式会社 | 治療用ガス投入用呼吸マスク |
US9486429B2 (en) * | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
FR2795644B1 (fr) * | 1999-07-02 | 2004-07-30 | Air Liquide Sante Int | Utilisations therapeutiques d'un melange helium/oxygene, en particulier dans le traitement de l'asthme |
DK1218049T3 (da) * | 1999-07-12 | 2007-01-29 | Capnia Inc | Anordning til lindring af hovedpiner, rhinitis og andre almindelige lidelser |
AU769210B2 (en) * | 1999-08-02 | 2004-01-22 | Duke University | Method for determining physiological effects of hemoglobin |
EP1128863B1 (en) | 1999-09-22 | 2006-04-19 | Instrumentarium Corporation | Improving oxygenation in subjects suffering impaired oxygenation |
US6694969B1 (en) | 1999-09-22 | 2004-02-24 | Instrumentarium Corp. | Method to improve oxygenation in subjects suffering impaired oxygenation |
US6612306B1 (en) | 1999-10-13 | 2003-09-02 | Healthetech, Inc. | Respiratory nitric oxide meter |
AU778522B2 (en) | 1999-10-29 | 2004-12-09 | Orion Corporation | Treatment or prevention of hypotension and shock |
SE9903985D0 (sv) * | 1999-11-03 | 1999-11-03 | Aga Ab | Use of nitric oxide |
US20060172017A1 (en) | 1999-11-08 | 2006-08-03 | Capnia, Incorporated | Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces |
US20070039615A1 (en) * | 1999-11-08 | 2007-02-22 | Capnia, Incorporated | Methods and apparatus for treating rhinitis |
US6959708B1 (en) * | 1999-11-08 | 2005-11-01 | Capnia, Incorporated | Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina and other ailments |
US6581599B1 (en) * | 1999-11-24 | 2003-06-24 | Sensormedics Corporation | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients |
US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
US6758214B2 (en) | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
US20030026766A1 (en) * | 2000-04-13 | 2003-02-06 | Mark Sanders | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
US6601580B1 (en) | 2000-06-28 | 2003-08-05 | The General Hospital Corporation | Enhancing therapeutic effectiveness of nitric oxide inhalation |
US6951215B1 (en) * | 2000-07-14 | 2005-10-04 | Tufts University | Drug delivery device for animals |
KR20030065463A (ko) * | 2000-08-11 | 2003-08-06 | 데이비드 알. 휘트록 | 질소 산화물 및 질소 산화물 전구체의 생산을 증가시키기위한 암모니아 산화 박테리아를 포함하는 조성물 및 이를이용하는 방법 |
AU2001296456A1 (en) | 2000-09-29 | 2002-04-08 | Healthetech, Inc. | Indirect calorimetry system |
US6668828B1 (en) | 2000-10-16 | 2003-12-30 | Pulmonox Technologies Corporations | System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient |
SE0004229D0 (sv) * | 2000-11-17 | 2000-11-17 | Aga Ab | Inhalation of nitric oxide |
US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US7335181B2 (en) * | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
AUPR315401A0 (en) | 2001-02-16 | 2001-03-15 | Resmed Limited | An apparatus for supplying clean breathable gas |
WO2002087673A1 (de) * | 2001-04-25 | 2002-11-07 | Messer Austria Gmbh | Aerosoldosiergerät |
US6749834B2 (en) * | 2001-06-19 | 2004-06-15 | World Precision Instruments, Inc. | Methods and apparatus for therapeutic treatment of respiratory, cardiac and other pathologies |
EP1429829B1 (en) * | 2001-09-05 | 2013-11-27 | Geno LLC | Nitric oxide generation |
US6575918B2 (en) | 2001-09-27 | 2003-06-10 | Charlotte-Mecklenburg Hospital | Non-invasive device and method for the diagnosis of pulmonary vascular occlusions |
US20030070674A1 (en) * | 2001-10-12 | 2003-04-17 | Bryan Perry | Use of aerosolized compounds in the treatment of exercise induced pulmonary hemorrhage in an equine |
GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
US6472390B1 (en) * | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
KR20040086267A (ko) * | 2002-01-11 | 2004-10-08 | 데이비드 알. 휘트록 | 암모니아 산화 박테리아를 포함하는 조성물 및 그를사용하는 방법 |
US20030170223A1 (en) * | 2002-02-01 | 2003-09-11 | Board Of Trustees Of Michigan State University | Pulmonary vasodilator surfactant compositions and method of use |
US7086397B2 (en) * | 2002-02-16 | 2006-08-08 | Graham Lindley Spruiell | Patient usable emergency medical kit |
US20060088942A1 (en) * | 2002-05-29 | 2006-04-27 | Stamler Jonathan S | Measuring nitric oxide in blood gases and treatments based thereon |
RS110504A (en) * | 2002-06-21 | 2007-02-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education, | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
JP2005531373A (ja) * | 2002-06-28 | 2005-10-20 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 治療薬送達装置及び方法 |
AU2003259897B2 (en) * | 2002-08-20 | 2008-04-03 | Aga Ab | Methods and devices for administration of therapeutic gases |
US7337776B2 (en) * | 2002-08-20 | 2008-03-04 | Aga Ab | Methods for easing pain and anxiety from atrial or ventricular defibrillation |
US7681572B2 (en) * | 2002-08-20 | 2010-03-23 | Aga Ab | Method and devices for administration of therapeutic gases |
US8001962B2 (en) * | 2002-08-23 | 2011-08-23 | Sheiman Ultrasonic Research Foundation Pty Ltd. | Nebulizing and drug delivery device |
US6869402B2 (en) * | 2002-08-27 | 2005-03-22 | Precision Pulsus, Inc. | Method and apparatus for measuring pulsus paradoxus |
US7828739B2 (en) * | 2002-08-27 | 2010-11-09 | Precision Pulsus, Inc. | Apnea detection system |
US7531133B2 (en) * | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
US20060128810A1 (en) * | 2002-10-10 | 2006-06-15 | Kyoto University | Remedies for allergic diseases |
CA2413834A1 (en) | 2002-12-10 | 2004-06-10 | 1017975 Alberta Limited | Nitric oxide gas generator |
US9138707B2 (en) | 2002-12-10 | 2015-09-22 | Sy Kimball | Portable, nitric oxide generator |
SE0300971D0 (sv) * | 2003-04-03 | 2003-04-03 | Aga Ab | Nitric oxide in treatment of inflammation |
US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
ATE372777T1 (de) * | 2003-07-09 | 2007-09-15 | Us Gov Health & Human Serv | Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen |
JP2007508247A (ja) * | 2003-09-26 | 2007-04-05 | ホイットロック,デービッド,アール. | アンモニア酸化細菌の使用方法 |
US7552731B2 (en) * | 2003-11-14 | 2009-06-30 | Remcore, Inc. | Remote control gas regulation system |
WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
US20050191245A1 (en) * | 2004-02-27 | 2005-09-01 | Adams Christopher P. | Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders |
EP1737482A4 (en) * | 2004-03-01 | 2010-09-15 | Lumen Therapeutics Llc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES |
US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
EP1732527A2 (en) * | 2004-03-17 | 2006-12-20 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
CA2563493A1 (en) * | 2004-05-11 | 2005-11-24 | Sensormedics Corporation | Intermittent dosing of nitric oxide gas |
US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
EP1789119B1 (en) * | 2004-08-18 | 2017-10-18 | Geno LLC | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
US7721729B2 (en) * | 2005-03-09 | 2010-05-25 | Ric Investments, Llc | Nebulizing drug delivery device for ventilator |
US7814901B2 (en) * | 2005-03-09 | 2010-10-19 | Ric Investments, Llc | Nebulizing drug delivery device with increased flow rate |
US7631643B2 (en) | 2005-03-09 | 2009-12-15 | Ric Investments, Llc | Nebulizing drug delivery device with interlock detection and temperature protection |
US8056557B2 (en) * | 2005-03-09 | 2011-11-15 | Ric Investments, Llc | Nebulizing drug delivery device with barrier |
US8557300B2 (en) * | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
ATE516086T1 (de) * | 2005-05-23 | 2011-07-15 | Biosonic Australia Pty Ltd | Vorrichtung zur zerstäubung und flüssigkeitsfiltration |
US8893717B2 (en) | 2005-09-21 | 2014-11-25 | Ino Therapeutics Llc | Systems and methods of administering a pharmaceutical gas to a patient |
US7523752B2 (en) | 2005-09-21 | 2009-04-28 | Ino Therapeutics, Llc | System and method of administering a pharmaceutical gas to a patient |
US7566308B2 (en) * | 2005-10-13 | 2009-07-28 | Cardiac Pacemakers, Inc. | Method and apparatus for pulmonary artery pressure signal isolation |
WO2007057763A2 (en) * | 2005-11-18 | 2007-05-24 | Pulmonox Technologies Corporation | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
ES2414957T3 (es) * | 2005-12-21 | 2013-07-23 | Solaeromed Inc. | Tratamiento de enfermedades respiratorias |
US8790715B2 (en) | 2006-02-16 | 2014-07-29 | Ino Therapeutics Llc | Method and apparatus for generating nitric oxide for medical use |
US20100313883A1 (en) * | 2006-04-20 | 2010-12-16 | Koninklijke Philips Electronics N.V. | Ultrasonic bebulilzer with metal coated ultrasonic genrator |
US11229746B2 (en) | 2006-06-22 | 2022-01-25 | Excelsior Medical Corporation | Antiseptic cap |
US9259535B2 (en) | 2006-06-22 | 2016-02-16 | Excelsior Medical Corporation | Antiseptic cap equipped syringe |
EP1903003B1 (de) * | 2006-07-05 | 2017-07-05 | BSN medical GmbH | Verfahren zur photolytischen Erzeugung von Stickstoffmonoxid |
US8079998B2 (en) * | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
KR20090087900A (ko) * | 2006-11-07 | 2009-08-18 | 더 제너럴 하스피탈 코포레이션 | 혈관작용성 산소운반체에 의해 유도되는 혈관수축의 감소 |
WO2008079993A2 (en) * | 2006-12-22 | 2008-07-03 | Ikaria, Inc. | Combinations of nitric oxide and sulfide and methods of use and manufacture thereof |
US20080193566A1 (en) * | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
US8166971B2 (en) * | 2007-03-15 | 2012-05-01 | Ric Investments, Llc | End-tidal gas estimation system and method |
US8176915B2 (en) * | 2007-03-15 | 2012-05-15 | Koninklijke Philips Electronics N.V. | End-tidal gas estimation system and method |
EP2131903B1 (en) * | 2007-03-23 | 2018-01-24 | Geno LLC | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
US7943667B2 (en) * | 2007-10-11 | 2011-05-17 | Duke University | Potentiating the effect of compound comprising nitric oxide |
WO2009079078A1 (en) | 2007-12-14 | 2009-06-25 | Labogroup S.A.S. | Delivering aerosolizable food products |
CA2710349A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
WO2009097343A1 (en) | 2008-01-28 | 2009-08-06 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
US8434475B2 (en) | 2008-01-31 | 2013-05-07 | Genosys, Inc. | Nitric oxide reactor and distributor apparatus and method |
US8720436B2 (en) * | 2008-01-31 | 2014-05-13 | Genosys, Inc. | Nitric oxide gel apparatus and method |
RU2528097C2 (ru) | 2008-01-31 | 2014-09-10 | Вандербилт Юнивёсити | Способы и составы для лечения субарахноидального кровоизлияния коронарной и артериальной аневризмы |
US9649467B2 (en) | 2008-01-31 | 2017-05-16 | Syk Technologies, Llc | Nitric oxide reactor and distributor apparatus and method |
KR20100135729A (ko) * | 2008-01-31 | 2010-12-27 | 반더빌트유니버시티 | 폐의 용태에 따른 치료 방법 |
US8501090B2 (en) * | 2008-03-24 | 2013-08-06 | Christian S. Minton | Anti-microbial gas apparatus and method |
US20100040703A1 (en) * | 2008-08-13 | 2010-02-18 | Chris Miller | Use of nitric oxide |
US8607785B2 (en) * | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
US10960168B2 (en) | 2008-08-21 | 2021-03-30 | Vero Biotech LLC | Delivery of high concentration nitric oxide |
GB2463883A (en) * | 2008-09-25 | 2010-03-31 | Pharma Patents Ltd | A pharmaceutical composition comprising an A-SMase inhibitor and an NO-donor |
US9078992B2 (en) | 2008-10-27 | 2015-07-14 | Pursuit Vascular, Inc. | Medical device for applying antimicrobial to proximal end of catheter |
AU2010248776B2 (en) * | 2009-05-15 | 2013-06-06 | Baudax Bio, Inc. | Sublingual dexmedetomidine compositions and methods of use thereof |
DK2435121T3 (en) | 2009-05-27 | 2017-07-24 | Ino Therapeutics Llc | DEVICE FOR CONNECTING AN INDEXED VALVE AND PRESSURE CONTAINER WITH A REQUIREMENT |
AU2010263098B2 (en) | 2009-06-22 | 2016-01-07 | VERO Biotech LLC. | Nitric oxide therapies |
CA2671029A1 (en) | 2009-06-30 | 2010-12-30 | James S. Baldassarre | Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension |
CA2781295C (en) * | 2009-11-20 | 2018-02-13 | Geno Llc | Nitric oxide delivery system |
US8887720B2 (en) | 2010-04-26 | 2014-11-18 | Geno Llc | Delivery of ultra pure nitric oxide (NO) |
DE102010016699A1 (de) | 2010-04-29 | 2011-11-03 | Maquet Gmbh & Co. Kg | Verfahren und Vorrichtung zur Applikation mindestens eines medizinischen Gases an einen mit Hilfe eines Beatmungsgeräts beatmeten Patienten |
US8685467B2 (en) | 2010-08-03 | 2014-04-01 | J. W. Randolph Miller | Nitric oxide generation, dilution, and topical application apparatus and method |
EP2613839B1 (en) * | 2010-09-10 | 2018-12-12 | INO Therapeutics LLC | Compositions, methods and articles concerning pharmaceutical nitric oxide and controlled patient delivery systems thereof |
WO2012037665A1 (en) | 2010-09-24 | 2012-03-29 | Oral Delivery Technology Ltd. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
EP2646365B1 (en) * | 2010-12-03 | 2016-08-03 | Koninklijke Philips N.V. | Method and arrangement for generating nitric oxide |
EP2661300B1 (en) | 2011-01-06 | 2017-10-04 | INO Therapeutics LLC | Gas delivery device and system |
US10445846B2 (en) * | 2011-04-14 | 2019-10-15 | Elwha Llc | Cost-effective resource apportionment technologies suitable for facilitating therapies |
US10853819B2 (en) * | 2011-04-14 | 2020-12-01 | Elwha Llc | Cost-effective resource apportionment technologies suitable for facilitating therapies |
FR2976260B1 (fr) † | 2011-06-09 | 2013-07-05 | Air Liquide | Procede de conditionnement de melanges no/n2 avec etapes de purge et rincage gazeux prealable |
EP2731658B1 (en) | 2011-07-12 | 2020-04-01 | Pursuit Vascular, Inc. | Device for delivery of antimicrobial agent into trans-dermal catheter |
WO2013052548A2 (en) | 2011-10-03 | 2013-04-11 | Nitric Generation Technologies Llc | Apparatus and method for generating nitric oxide in controlled and accurate amounts |
JP6389125B2 (ja) * | 2011-11-07 | 2018-09-12 | ザ ジェネラル ホスピタル コーポレイション | 赤血球の処理法 |
PE20142314A1 (es) | 2011-12-11 | 2015-01-23 | Recro Pharma Inc | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas |
CN104411317A (zh) | 2012-03-15 | 2015-03-11 | Ino治疗有限责任公司 | 用于施用高浓度一氧化碳的方法 |
FR2991025B1 (fr) | 2012-05-24 | 2014-07-04 | Air Liquide Sante Int | Conditionnement d'un melange gazeux no/azote a haute concentration en no |
FR2991026B1 (fr) | 2012-05-24 | 2014-07-04 | Air Liquide Sante Int | Conditionnement a haute pression d'un melange gazeux no/azote |
FR2990858B1 (fr) * | 2012-05-24 | 2015-04-03 | Air Liquide Sante Int | Melange gazeux no/azote a teneur elevee en no pour traiter les detresses respiratoires hypoxemiantes severes |
US9795756B2 (en) | 2012-12-04 | 2017-10-24 | Mallinckrodt Hospital Products IP Limited | Cannula for minimizing dilution of dosing during nitric oxide delivery |
EP3636306B1 (en) | 2012-12-04 | 2024-01-31 | Mallinckrodt Hospital Products IP Limited | Cannula for minimizing dilution of dosing during nitric oxide delivery |
US20160008394A1 (en) | 2013-02-28 | 2016-01-14 | Aires Pharmaceuticals, Inc. | Inorganic nitrite to improve cardiopulmonary hemodynamics |
KR102317818B1 (ko) | 2013-03-15 | 2021-10-26 | 더 제너럴 하스피탈 코포레이션 | 산화질소의 흡기 합성 |
BR112015022468B1 (pt) | 2013-03-15 | 2022-11-01 | The General Hospital Corporation | Aparelho e método para síntese do gás óxido nítrico para inalação |
US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
WO2014210030A2 (en) | 2013-06-25 | 2014-12-31 | Ino Therapeutics Llc | Methods of reducing the risk of mortality associated with a medical treatment |
US9522247B2 (en) | 2013-06-28 | 2016-12-20 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Method of treating a patient having pulmonary hypertension by long term NO therapy |
US9492626B2 (en) | 2013-06-28 | 2016-11-15 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Breathing assistance assemblies suitable for long term no therapy |
US9517318B2 (en) | 2013-06-28 | 2016-12-13 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Method of delivering medical gases via a nasal cannula assembly with flow control passage communicating with a deformable reservoir |
US9486600B2 (en) | 2013-06-28 | 2016-11-08 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Nasal cannula assembly with inhalation valves communicating with a deformable reservoir |
US9566407B2 (en) | 2013-06-28 | 2017-02-14 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Nasal cannula assembly with flow control passage communicating with a deformable reservoir |
US9522248B2 (en) | 2013-06-28 | 2016-12-20 | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Breathing assistance apparatus for delivery of nitric oxide to a patient by means of a nasal cannula assembly with flow control passage |
WO2015009615A1 (en) * | 2013-07-15 | 2015-01-22 | Vanderbilt University | Methods for the production of collagen iv |
FR3015000B1 (fr) | 2013-12-12 | 2016-05-27 | Air Liquide Sante (International) | Systeme de stockage et de distribution de melanges no/azote |
HUE049323T2 (hu) | 2014-02-10 | 2020-09-28 | Respivant Sciences Gmbh | Hízósejt-stabilizálók tüdõbetegség kezelésére |
EP3104853B1 (en) | 2014-02-10 | 2019-10-02 | Respivant Sciences GmbH | Mast cell stabilizers treatment for systemic disorders |
US20150290417A1 (en) * | 2014-04-09 | 2015-10-15 | 12th Man Technologies. Inc. | System and Method for High Concentration Nitric Oxide Delivery |
KR20230165365A (ko) | 2014-04-15 | 2023-12-05 | 에이오바이오미 엘엘씨 | 암모니아-산화 니트로소모나스 유트로파 균주 d23 |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
EP2937089A1 (en) | 2014-04-23 | 2015-10-28 | Linde AG | Device for the treatment of, treatment of complications arising from, and/or prevention of respiratory disorders |
CN107073239A (zh) | 2014-10-20 | 2017-08-18 | 通用医疗公司 | 用于合成一氧化氮的系统和方法 |
US10213572B2 (en) | 2014-10-20 | 2019-02-26 | Vero Biotech LLC | Nitrogen dioxide storage cassette |
CN107735135B (zh) | 2015-04-02 | 2020-06-26 | 希尔-罗姆服务私人有限公司 | 用于呼吸装置的歧管 |
AU2016262400B2 (en) | 2015-05-08 | 2021-01-21 | Icu Medical, Inc. | Medical connectors configured to receive emitters of therapeutic agents |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
KR102363923B1 (ko) * | 2015-09-09 | 2022-02-21 | 어드밴스드 인헐레이션 테라피즈 (에이아이티) 리미티드 | 세기관지염이 있는 유아를 위한 산화질소 흡입 치료 |
US9744190B2 (en) | 2016-01-15 | 2017-08-29 | Thomas Tait | Continuous gas generator |
WO2017132275A1 (en) | 2016-01-27 | 2017-08-03 | Syk Technologies, Llc | Nitric oxide topical application apparatus and methods |
CA3012180A1 (en) * | 2016-02-12 | 2017-08-17 | Mallinckrodt Hospital Products IP Limited | Use and monitoring of inhaled nitric oxide with left ventricular assist devices |
US11617850B2 (en) | 2016-03-25 | 2023-04-04 | The General Hospital Corporation | Delivery systems and methods for electric plasma synthesis of nitric oxide |
WO2018044942A1 (en) | 2016-08-31 | 2018-03-08 | Patara Pharma, LLC | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
PL3525865T3 (pl) | 2016-10-14 | 2023-02-06 | Icu Medical, Inc. | Nasadki dezynfekcyjne dla łączników medycznych |
RU2020113418A (ru) | 2017-02-27 | 2020-10-05 | Cёрд Поул, Инк. | Системы и способы получения оксида азота в амбулаторных условиях |
WO2018157172A1 (en) | 2017-02-27 | 2018-08-30 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
US10239038B2 (en) | 2017-03-31 | 2019-03-26 | The General Hospital Corporation | Systems and methods for a cooled nitric oxide generator |
WO2018204206A2 (en) | 2017-05-01 | 2018-11-08 | Icu Medical, Inc. | Medical fluid connectors and methods for providing additives in medical fluid lines |
CA3081341A1 (en) * | 2017-11-02 | 2019-05-09 | Beyond Air, Inc. | Inhalation of nitric oxide |
JP6618976B2 (ja) * | 2017-11-14 | 2019-12-11 | イノ セラピューティクス エルエルシー | 指標付弁と襟部を有する加圧容器組立体を係合するため、かつ薬物送達を調整するための装置と流体連通したプランジャ組立体により直線的に作動させるための装置および方法 |
US11541221B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Tubing set with antimicrobial properties |
US11517732B2 (en) | 2018-11-07 | 2022-12-06 | Icu Medical, Inc. | Syringe with antimicrobial properties |
US11400195B2 (en) | 2018-11-07 | 2022-08-02 | Icu Medical, Inc. | Peritoneal dialysis transfer set with antimicrobial properties |
US11534595B2 (en) | 2018-11-07 | 2022-12-27 | Icu Medical, Inc. | Device for delivering an antimicrobial composition into an infusion device |
US11541220B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Needleless connector with antimicrobial properties |
AU2019384564B2 (en) | 2018-11-21 | 2023-11-23 | Icu Medical, Inc. | Antimicrobial device comprising a cap with ring and insert |
JP7111404B2 (ja) * | 2019-04-19 | 2022-08-02 | 国立研究開発法人物質・材料研究機構 | 窒素系ガス徐放剤及びこれで構成された窒素系ガス徐放体、並びに該徐放体を用いた窒素系ガスの徐放方法、呼吸器具、包装体及び徐放装置 |
EP3969415A4 (en) | 2019-05-15 | 2023-08-16 | Third Pole, Inc. | ELECTRODES FOR NITRIC OXIDE GENERATION |
CN114375284A (zh) | 2019-05-15 | 2022-04-19 | 第三极股份有限公司 | 用于生成一氧化氮的系统和方法 |
FR3103110B1 (fr) | 2019-11-15 | 2021-10-08 | Air Liquide | Dispositif de fourniture de gaz thérapeutique, en particulier de NO ou de N2O, à un patient |
CA3162050A1 (en) | 2019-11-25 | 2021-06-03 | Beyond Air, Inc. | Methods employing gaseous nitric oxide for inhibiting tumor growth |
WO2021142472A1 (en) | 2020-01-11 | 2021-07-15 | Third Pole, Inc. | Systems and methods for nitric oxide generation with humidity control |
US20210395905A1 (en) | 2020-06-18 | 2021-12-23 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
US20220143080A1 (en) * | 2020-11-12 | 2022-05-12 | Thermolife International, Llc | Methods of increasing blood oxygen saturation |
US11865139B2 (en) | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
EP4255552A1 (en) | 2020-12-07 | 2023-10-11 | ICU Medical, Inc. | Peritoneal dialysis caps, systems and methods |
US11975139B2 (en) | 2021-09-23 | 2024-05-07 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
FR3127408B1 (fr) | 2021-09-29 | 2024-05-10 | Inosystems | Chariot hospitalier de transport de bouteille de gaz, notamment de NO médical |
EP4209243A1 (fr) | 2022-01-05 | 2023-07-12 | Inosystems | Dispositif de délivrance de no avec système de dosage d'urgence |
FR3137841A1 (fr) | 2022-07-18 | 2024-01-19 | Inosystems | Dispositif de délivrance de NO avec système de dosage d’urgence |
FR3131538A1 (fr) | 2022-01-05 | 2023-07-07 | Inosystems | Dispositif de délivrance de NO avec système de dosage d’urgence |
FR3132025A1 (fr) | 2022-01-24 | 2023-07-28 | Inosystems | Cartouche de stockage d’un mélange NO/azote et installation de fourniture de gaz associée |
FR3133318B1 (fr) | 2022-03-09 | 2024-03-22 | Inosystems | Dispositif de délivrance de NO avec circuit de secours à débit contrôlé |
FR3133315B1 (fr) | 2022-03-09 | 2024-03-22 | Inosystems | Appareil de délivrance de NO à deux sorties de gaz |
FR3133317B1 (fr) | 2022-03-09 | 2024-03-01 | Inosystems | Appareil de délivrance de NO avec système de ventilation manuelle |
FR3133316B1 (fr) | 2022-03-09 | 2024-04-12 | Inosystems | Dispositif de délivrance de NO avec circuit de secours |
FR3136986A1 (fr) | 2022-06-24 | 2023-12-29 | Inosystems | Affichage de la dose de NO par un dispositif de fourniture de NO en phase de pause |
FR3138773A1 (fr) | 2022-08-11 | 2024-02-16 | Inosystems | Installation de fourniture de gaz comprenant un ventilateur médical et un dispositif de délivrance de NO avec un système de dosage d’urgence |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3367332A (en) * | 1965-08-27 | 1968-02-06 | Gen Electric | Product and process for establishing a sterile area of skin |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3785377A (en) * | 1970-11-12 | 1974-01-15 | S Jorgensen | Plant, preferably for anaesthesia |
US3745991A (en) * | 1971-02-22 | 1973-07-17 | Champion Spark Plug Co | Environmental contamination control device |
US4010897A (en) * | 1976-03-31 | 1977-03-08 | Charles F. Kettering Foundation | Method and apparatus for home production and application of nitrogen fertilizer |
IL57239A (en) * | 1979-05-08 | 1982-04-30 | Alamaro Moshe | Production of nitric oxides |
US4297123A (en) * | 1980-02-07 | 1981-10-27 | Wyse Harold G | Method and apparatus for producing a nitrate fertilizer |
US4336798A (en) * | 1980-10-06 | 1982-06-29 | Anthony V. Beran | Medical corrugated respiratory tube |
SE438261B (sv) * | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
US4484577A (en) * | 1981-07-23 | 1984-11-27 | Key Pharmaceuticals, Inc. | Drug delivery method and inhalation device therefor |
US4534343A (en) * | 1984-01-27 | 1985-08-13 | Trutek Research, Inc. | Metered dose inhaler |
US4592348A (en) * | 1984-12-17 | 1986-06-03 | Waters Iv William C | Aerosol inhaler |
US4675174A (en) * | 1985-08-16 | 1987-06-23 | Alza Corporation | Veterinary dispenser delivering beneficial agent by gas power generated in situ |
US4852561A (en) * | 1988-07-27 | 1989-08-01 | Sperry C R | Inhalation device |
US4877589A (en) * | 1988-09-19 | 1989-10-31 | Hare Louis R O | Nitrogen fixation by electric arc and catalyst |
US4915915A (en) * | 1988-10-11 | 1990-04-10 | Treharne Richard W | Water-powdered piezoelectric unit for producing nitrogen fertilizer |
US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5007419A (en) * | 1989-09-25 | 1991-04-16 | Allan Weinstein | Inhaler device |
US5178138A (en) * | 1990-09-11 | 1993-01-12 | Walstrom Dennis R | Drug delivery device |
US5155137A (en) * | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
US5187305A (en) * | 1990-11-26 | 1993-02-16 | Glaxo Inc. | S-nitroso-N-alkonoylpenicillamines |
US5396882A (en) * | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
DK0786264T3 (da) * | 1990-12-05 | 2008-03-10 | Gen Hospital Corp | Anordninger til behandling af pulmonal vasokonstriktion og astma |
IL101406A (en) * | 1991-03-29 | 1998-02-08 | Brigham & Womens Hospital | Pharmaceutical compositions containing s-nitrosothiol derivatives |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
AU3237193A (en) * | 1991-12-11 | 1993-07-19 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
-
1991
- 1991-12-05 DK DK97105021T patent/DK0786264T3/da active
- 1991-12-05 DE DE69133584T patent/DE69133584T4/de not_active Expired - Lifetime
- 1991-12-05 EP EP07119550A patent/EP1875917A3/en not_active Withdrawn
- 1991-12-05 DE DE200812000012 patent/DE122008000012I2/de active Active
- 1991-12-05 JP JP4502844A patent/JP2701978B2/ja not_active Expired - Lifetime
- 1991-12-05 ES ES04029366.4T patent/ES2288660T5/es not_active Expired - Lifetime
- 1991-12-05 ES ES97105021T patent/ES2132043T3/es not_active Expired - Lifetime
- 1991-12-05 EP EP97105021A patent/EP0786264B1/en not_active Revoked
- 1991-12-05 ES ES92902708T patent/ES2082732T3/es not_active Expired - Lifetime
- 1991-12-05 DK DK04029366.4T patent/DK1516639T4/en active
- 1991-12-05 DE DE0560928T patent/DE560928T1/de active Pending
- 1991-12-05 SG SG1996002651A patent/SG47527A1/en unknown
- 1991-12-05 DE DE0786264T patent/DE786264T1/de active Pending
- 1991-12-05 DE DE69133584A patent/DE69133584D1/de not_active Expired - Lifetime
- 1991-12-05 AT AT92902708T patent/ATE158509T1/de active
- 1991-12-05 DE DE122007000103C patent/DE122007000103I1/de active Pending
- 1991-12-05 CA CA002097823A patent/CA2097823C/en not_active Expired - Lifetime
- 1991-12-05 DK DK92902708.4T patent/DK0560928T3/da active
- 1991-12-05 DE DE69127756T patent/DE69127756T2/de not_active Expired - Lifetime
- 1991-12-05 DE DE2002199002 patent/DE10299002I1/de active Pending
- 1991-12-05 EP EP20040029366 patent/EP1516639B2/en not_active Expired - Lifetime
- 1991-12-05 DE DE69133575T patent/DE69133575T2/de not_active Expired - Lifetime
- 1991-12-05 WO PCT/US1991/009111 patent/WO1992010228A1/en not_active Application Discontinuation
- 1991-12-05 AT AT04029366T patent/ATE367842T2/de active
- 1991-12-05 AU AU91498/91A patent/AU657726B2/en not_active Expired
- 1991-12-05 AT AT97105021T patent/ATE376850T1/de active
- 1991-12-05 EP EP92902708A patent/EP0560928B1/en not_active Revoked
-
1994
- 1994-09-15 EE EE9400192A patent/EE03119B1/xx unknown
- 1994-12-09 US US08/353,508 patent/US5873359A/en not_active Expired - Lifetime
-
1995
- 1995-02-10 US US08/384,792 patent/US5485827A/en not_active Expired - Lifetime
-
1996
- 1996-06-30 GR GR960300032T patent/GR960300032T1/el unknown
-
1997
- 1997-02-20 JP JP03678597A patent/JP3510755B2/ja not_active Expired - Lifetime
- 1997-09-25 GR GR970402498T patent/GR3024865T3/el unknown
-
1998
- 1998-08-24 LV LVP-98-169A patent/LV12201B/en unknown
- 1998-09-24 HK HK99105833A patent/HK1020686A1/xx not_active IP Right Cessation
- 1998-09-24 HK HK98110945A patent/HK1010101A1/xx not_active IP Right Cessation
-
1999
- 1999-01-01 GR GR990300018T patent/GR990300018T1/el unknown
-
2002
- 2002-01-24 LU LU90886C patent/LU90886I2/xx unknown
- 2002-01-30 NL NL300081C patent/NL300081I2/nl unknown
- 2002-07-26 JP JP2002217936A patent/JP3718491B2/ja not_active Expired - Lifetime
-
2005
- 2005-09-22 HK HK05108350A patent/HK1076407A1/xx not_active IP Right Cessation
-
2007
- 2007-12-14 NL NL300327C patent/NL300327I2/nl unknown
- 2007-12-21 LU LU91404C patent/LU91404I2/fr unknown
-
2008
- 2008-04-01 NL NL300342C patent/NL300342I1/nl unknown
- 2008-04-30 LU LU91423C patent/LU91423I2/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3367332A (en) * | 1965-08-27 | 1968-02-06 | Gen Electric | Product and process for establishing a sterile area of skin |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003186A1 (fr) * | 1996-07-18 | 1998-01-29 | Sumitomo Seika Chemicals Co., Ltd. | Gaz mixte contenant du monoxyde d'azote destine a des applications medicales, et son procede de preparation |
JP2003524630A (ja) * | 1999-09-08 | 2003-08-19 | デューク ユニバーシティ | No基化合物で心肺疾病を処置する方法 |
JP2005504001A (ja) * | 2001-02-14 | 2005-02-10 | デューク・ユニバーシティ | Gsnoの充足を起こすガス状薬剤による肺疾患の処置 |
JP4652664B2 (ja) * | 2001-02-14 | 2011-03-16 | デューク ユニバーシティ | Gsnoの充足を起こすガス状薬剤による肺疾患の処置 |
JP2014121634A (ja) * | 2008-08-21 | 2014-07-03 | Geno Llc | 高所病を最小限に抑える及び治療するための装置及び方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3718491B2 (ja) | 吸入用装置 | |
US5570683A (en) | Methods and devices for treating pulmonary vasoconstriction and asthma | |
US5823180A (en) | Methods for treating pulmonary vasoconstriction and asthma | |
Swenson et al. | Effects of carbonic anhydrase inhibition on ventilation-perfusion matching in the dog lung. | |
Brown et al. | Pathophysiological responses following phosgene exposure in the anaesthetized pig | |
Lee et al. | Bronchodilator aerosol administered by metered dose inhaler and spacer in subacute neonatal respiratory distress syndrome. | |
Matamis et al. | Free Papers | |
Pearl | Inhaled nitric oxide. | |
Rosengart | Liquid Ventilation | |
JPS59500900A (ja) | 薬剤の送出装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081003 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
S212 | Written request for registration of transfer of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315213 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
S211 | Written request for registration of transfer of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314213 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
S211 | Written request for registration of transfer of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314213 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101003 Year of fee payment: 13 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
S211 | Written request for registration of transfer of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314213 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101003 Year of fee payment: 13 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101003 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 14 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 14 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term |